Jason M Glanz1,2, Christina L Clarke1, Matthew F Daley1, Jo Ann Shoup1, Simon J Hambidge3, Joshua T B Williams3, Holly C Groom4, Elyse O Kharbanda5, Nicola P Klein6, Lisa A Jackson7, Bruno J Lewin8, David L McClure9, Stanley Xu8, Frank DeStefano10. 1. Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado. 2. Department of Epidemiology, Colorado School of Public Health, University of Colorado, Aurora, Colorado. 3. Denver Health and Hospital Authority, Denver, Colorado. 4. Kaiser Permanente Center for Health Research, Northwest Kaiser Permanente, Portland, Oregon. 5. HealthPartners Institute, Minneapolis, Minnesota. 6. Kaiser Permanente Division of Research, Kaiser Permanente of Northern California, Oakland, California. 7. Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington. 8. Kaiser Permanente Department of Research and Evaluation, Kaiser Permanente of Southern California, Pasadena, California. 9. Marshfield Clinic Research Foundation Institute, Marshfield, Wisconsin. 10. Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
OBJECTIVES: Safety studies assessing the association between the entire recommended childhood immunization schedule and autoimmune diseases, such as type 1 diabetes mellitus (T1DM), are lacking. To examine the association between the recommended immunization schedule and T1DM, we conducted a retrospective cohort study of children born between 2004 and 2014 in 8 US health care organizations that participate in the Vaccine Safety Datalink. METHODS: Three measures of the immunization schedule were assessed: average days undervaccinated (ADU), cumulative antigen exposure, and cumulative aluminum exposure. T1DM incidence was identified by International Classification of Disease codes. Cox proportional hazards models were used to analyze associations between the 3 exposure measures and T1DM incidence. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) were calculated. Models were adjusted for sex, race and ethnicity, birth year, mother's age, birth weight, gestational age, number of well-child visits, and study site. RESULTS: In a cohort of 584 171 children, the mean ADU was 38 days, the mean cumulative antigen exposure was 263 antigens (SD = 54), and the mean cumulative aluminum exposure was 4.11 mg (SD = 0.73). There were 1132 incident cases of T1DM. ADU (aHR = 1.01; 95% CI, 0.99-1.02) and cumulative antigen exposure (aHR = 0.98; 95% CI, 0.97-1.00) were not associated with T1DM. Cumulative aluminum exposure >3.00 mg was inversely associated with T1DM (aHR = 0.77; 95% CI, 0.60-0.99). CONCLUSIONS: The recommended schedule is not positively associated with the incidence of T1DM in children. These results support the safety of the recommended childhood immunization schedule.
OBJECTIVES: Safety studies assessing the association between the entire recommended childhood immunization schedule and autoimmune diseases, such as type 1 diabetes mellitus (T1DM), are lacking. To examine the association between the recommended immunization schedule and T1DM, we conducted a retrospective cohort study of children born between 2004 and 2014 in 8 US health care organizations that participate in the Vaccine Safety Datalink. METHODS: Three measures of the immunization schedule were assessed: average days undervaccinated (ADU), cumulative antigen exposure, and cumulative aluminum exposure. T1DM incidence was identified by International Classification of Disease codes. Cox proportional hazards models were used to analyze associations between the 3 exposure measures and T1DM incidence. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) were calculated. Models were adjusted for sex, race and ethnicity, birth year, mother's age, birth weight, gestational age, number of well-child visits, and study site. RESULTS: In a cohort of 584 171 children, the mean ADU was 38 days, the mean cumulative antigen exposure was 263 antigens (SD = 54), and the mean cumulative aluminum exposure was 4.11 mg (SD = 0.73). There were 1132 incident cases of T1DM. ADU (aHR = 1.01; 95% CI, 0.99-1.02) and cumulative antigen exposure (aHR = 0.98; 95% CI, 0.97-1.00) were not associated with T1DM. Cumulative aluminum exposure >3.00 mg was inversely associated with T1DM (aHR = 0.77; 95% CI, 0.60-0.99). CONCLUSIONS: The recommended schedule is not positively associated with the incidence of T1DM in children. These results support the safety of the recommended childhood immunization schedule.
Authors: F DeStefano; J P Mullooly; C A Okoro; R T Chen; S M Marcy; J I Ward; C M Vadheim; S B Black; H R Shinefield; R L Davis; K Bohlke Journal: Pediatrics Date: 2001-12 Impact factor: 7.124
Authors: C R Cardwell; L C Stene; G Joner; O Cinek; J Svensson; M J Goldacre; R C Parslow; P Pozzilli; G Brigis; D Stoyanov; B Urbonaite; S Sipetić; E Schober; C Ionescu-Tirgoviste; G Devoti; C E de Beaufort; K Buschard; C C Patterson Journal: Diabetologia Date: 2008-02-22 Impact factor: 10.122
Authors: Jason M Glanz; Sophia R Newcomer; Komal J Narwaney; Simon J Hambidge; Matthew F Daley; Nicole M Wagner; David L McClure; Stan Xu; Ali Rowhani-Rahbar; Grace M Lee; Jennifer C Nelson; James G Donahue; Allison L Naleway; James D Nordin; Marlene M Lugg; Eric S Weintraub Journal: JAMA Pediatr Date: 2013-03-01 Impact factor: 16.193
Authors: Thomas Harder; Katharina Roepke; Natasha Diller; Yvonne Stechling; Joachim W Dudenhausen; Andreas Plagemann Journal: Am J Epidemiol Date: 2009-04-10 Impact factor: 4.897
Authors: Dana Dabelea; Elizabeth J Mayer-Davis; Sharon Saydah; Giuseppina Imperatore; Barbara Linder; Jasmin Divers; Ronny Bell; Angela Badaru; Jennifer W Talton; Tessa Crume; Angela D Liese; Anwar T Merchant; Jean M Lawrence; Kristi Reynolds; Lawrence Dolan; Lenna L Liu; Richard F Hamman Journal: JAMA Date: 2014-05-07 Impact factor: 56.272
Authors: Eileen Morgan; Sophia R Halliday; Gemma R Campbell; Chris R Cardwell; Chris C Patterson Journal: Diabetologia Date: 2015-11-12 Impact factor: 10.122
Authors: Sebastian Ciężki; Emilia Kurpiewska; Artur Bossowski; Barbara Głowińska-Olszewska Journal: Front Endocrinol (Lausanne) Date: 2022-06-16 Impact factor: 6.055